alva10%2Bbetter%2Bheader.jpg

Alva10

Moving diagnostics to the forefront of precision medicine

At Alva10, we are unleashing the innovation that lies within the knowledge gap between healthcare purchasers and technology companies. These innovations are critical to pushing Precision Medicine forward, and optimizing spiraling healthcare spend.

WHAT WE DO

Alva10 reduces ineffective therapeutic spend via customized solutions that provide advance knowledge of patients’ ability to respond to costly therapies before they are given.

To do this, we innovated a new business model to restructure the relationship between health insurance payers and Precision Medicine technology companies. The result of this new way of doing business is a broad range of completely novel healthcare tools (diagnostics, devices, apps) that directly solve the largest clinical and economic challenges for payers and providers. We enable our payer/provider partners to source innovations for their greatest needs directly from us. And our industry-leading asset of Precision Medicine technology curation ensures that those partners receive the best-in-class tool for their particular problem.

The healthcare system today is confounding. In no other industry can the payer not give the supplier their vendor requirements. Alva10 is fundamentally changing that.
— Pharmacy Director, Health Insurance Company

how we partner

Alva10’s innovative business model partners payers with technology companies to solve the greatest challenges of both parties. By facilitating the process by which technology companies design fit-for-purpose solutions for payers and providers, technology companies’ greatest commercial challenges are also alleviated.

In this age of healthcare, the scientific challenge is no longer the greatest hurdle. Patient access, provider confidence, and payer approval are the critical components of a successful go-to-market approach.

website1.jpg
 
Hannah Mamuszka headshot current 1.jpg

hannah mamuszka - FOUNDER & ceo

Hannah has spent her 20+ year career in diagnostics- both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space.  Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Lena Chaihorsky photo cropped[69863].jpg

Lena Chaihorsky - CO-FOUNDER & vp pAYER innovation

Lena is dedicated to realigning the financial incentives in our healthcare system to enable the development and adoption of market-shifting innovations. With a background in biology and mathematics from Tufts, she is a skilled healthcare executive with a proven track record of developing and executing value based reimbursement strategies for diagnostics companies. Lena has extensive leadership experience in sales, national contracting, and all aspects of reimbursement within start-up and global companies, most recently AmniSure and QIAGEN. Lena’s work on commercial approaches to health economics data analysis has led to her recent appointment on the World Economic Forum’s workgroup dedicated to the economics of rare disease data federations.

JBlakeLong cropped[69864].jpg

BLAKE LONG, MD MBA - cHIEF MEDICAL OFFICER

Blake is focused on driving innovation in clinical science and health care delivery through both entrepreneurial ecosystem development and capital deployment based on experience in health care delivery, payment and investing.  He is focused on supporting early stage health care companies by providing clinical expertise and strategy analysis for both provider and payer markets.  Blake previously served as Chief Clinical Officer of Mosaic Health Solutions and Echo Health Ventures, the venture capital/private equity investment group of BlueCross BlueShield of NC and Cambia Health Solutions, evaluating investment opportunities and working with portfolio companies on collaborations with providers and insurers. Prior to Echo, Blake served for 20 years as a practicing pediatric cardiologist at Savannah Children’s Heart Center and as a clinical professor at Mercer University School of Medicine. He earned his BA and his MD from Duke University, and then completed his clinical training at Walter Reed Army Medical Center and Duke Medical Center. He received his MBA from Duke's Fuqua School of Business in December of 2015, and now serves as an Adjunct Professor at Fuqua in the Health Sector Management Program.

 

hear us live

see alva10 in action at any of the following events.

FALL 2019

Alva10 @ the Companion Diagnostics Forum, Princeton NJ, Oct 30

Think CDx deals are good for Dx companies? Come hear Alva10’s CEO deliver the counterargument and chart a path forward for change in this space with a talk entitled “Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders” . CDx Forum runs Oct 29-30, agenda here

Alva10 @ HLTH, Las Vegas - Oct 27-30

Don’t miss Alva10 in the exhibit hall of HLTH this year! And be sure to catch the packed agenda and speaker lineup of this emerging must-attend conference in healthcare. Agenda here

Alva10 @ FDA, Medical Device Epidemiology Network - Oct 21

Join the Medical Device Epidemiology Network (MDEpiNet) ‘s annual meeting at FDA in Silver Spring, MD Oct 21-23! Alva10’s CEO will be talking about the need for novel devices to optimize therapeutic assignment. Link here

Alva10 @ Becker’s Hospital Review, Chicago - Oct 10

Come hear CEO Hannah Mamuszka discuss the financial challenges to overcome in realizing Precision Medicine at Becker’s 5TH Annual Health IT + Revenue Cycle Conference in Chicago this

Alva10 @ AdvaMed’s MedTech Conference, Boston - Sept 23

Don’t miss AdvaMed’s ever-growing MedTech conference! Come catch Lena Chaihorsky moderating an expert panel on communicating the value of diagnostics to achieve market access and commercial success. Full agenda here

SPRING 2019

Don’t miss Alva10@ BIO!

Add these two panels to your BIO agenda to hear Hannah Mamuszka speak on Innovative Models for Real World Evidence and Harnessing the Potential of Exosomes, June 4-5 at the annual BIO convention in Philadelphia.

Alva10 hits stage at MedCity Invest, talks bringing Precision Medicine into the clinic

CEO Hannah Mamuszka will be moderating a panel at the annual MedCity INVEST conference in Chicago, IL on April 23. Agenda here.

Alva10 hits the radio waves! Listen to our Precision Medicine podcast episode

Have 20 minutes? Get the full download on how diagnostics can take their place at the forefront of Precision Medicine here and leave us a comment on Twitter!

Front page: Alva10’s MedCity News piece on Dx reimbursement & Precision Medicine

Read Lena Chaihorsky’s recent piece for MedCity News here and let us know what you think on Twitter @DxforPM

2018 - 2017

Alva10 presents on game-changing business models in Precision Medicine at HITLAB’s Innovator’s Summit

VP Lena Chaihorsky presents Alva10’s business model for Precision Medicine and draws parallels in the current state of the digital health industry. Agenda here.

Don’t miss the latest installment of ‘Mission Possible’: An Unlikely Alliance

Read Hannah Mamuszka’s piece on why and how PBMs and diagnostic companies can find synergies in the healthcare market in this popular column for the Journal of Precision Medicine - here.

MedTechConference asks the tough questions on CDx Panel

VP Lena Chaihorsky joins other industry thought leaders on a panel discussing the evolving role of diagnostics in Precision Medicine, and how the industry can control its own destiny in Companion Diagnostics. Agenda here - this #MedTechCon promises to be the biggest yet!

Alva10 talks Payer Engagement at AdvaMed's Payment Policy Conference

VP Lena Chaihorsky to moderate panel on early payer engagement at AdvaMed's annual Payment Policy Conference in Washington, DC. Agenda here - see you there!

'Mission Possible' gets 'Discovered' by Bruce Quinn!

Many thanks to Bruce Quinn for his mention of Hannah Mamuszka's article series 'Mission Possible' in his popular blog 'Discoveries in Health Policy'! Bruce is a nationally renowned expert in Medicare policy and a respected voice in the Precision Medicine community. We appreciate the support, Bruce!

See you soon, AdvaMed! Alva10 at AdvaMed's Working with Private Payers Workshop

Alva10 will be showcasing various diagnostic development projects and speaking on the value of payer engagement at AdvaMed's annual Payer workshop. See you in D.C. on Dec 12! Details here

Mark Your Calendars! Alva10 at the Q1 Diagnostic Coverage & Reimbursement Conference: Boston, MA 

Join the Alva10 team on December 4 at 2 PM as they discuss value based care and coming to consensus with payers on diagnostics. Conference runs from December 4-5. Download full agenda here

Don't Miss Us! Alva10 at the WorldCDx Conference: Boston, MA

Join the Alva10 team on Tuesday, October 17 for a workshop on the evolving role of In Vitro Diagnostics in Precision Medicine. Agenda here

Mission Possible: Moving Diagnostics to the Forefront of Precision Medicine

Follow along in the Journal of Precision Medicine as Hannah Mamuszka charts out the history of diagnostics in Precision Medicine and new paths forward in the age of value based care. New to the periodical? See the first installment here.

Don't Miss Us! Alva10 at the Precision Medicine Leaders Summit: San Diego, CA

Join the Alva10 team on Wednesday, August 23 at 5 PM for a 'Mission Possible' Roundtable on bringing diagnostics to the forefront of Precision Medicine. Conference runs from August 21-24. Full agenda

Alva10 Founder named one of Top 5 Women to Watch in Boston Biotech

Alva10 would like to thank Leah Kinthaert for naming Founder Hannah Mamuszka to Future of BioPharma's Top 5 Women to Watch in Boston Biotech List!

Read the full piece here

 

Contact Us

Are you a tech company, payer, press, or potential partner?

get in touch with us here and we’ll get right back to you.

Name *
Name